Page 12 - Flipbook
P. 12
Adjuvant Therapy in RCC: 1 win and 3 losses…
100
90
80
70
DFS, % 60
50
40
30 Pembro: HR 0.63; p < 0.0001 Atezo: HR 0.93; p = 0.49
20
Pembro
10
Placebo
0
0 5 10 15 20 25 30 35 40 45 50
Months
No. at risk
Pembro 496 458 416 389 361 255 135 77 37 0 0
Placebo 498 437 389 356 325 230 125 74 33 1 0
Disease-free probability (%) 100
90
80
70
60
50
Neo/adjuvant Nivo: HR: 0.97; p = 0.43 40 Ipi/Nivo: HR 0.92; p = 0.53
30
20
10
0
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54
Months
No. at risk
I
NIVO+IP 405 378 337 316 299 289 270 259 224 203 150 125 89 73 42 34 13 9 0
Placebo 411 391 340 315 299 293 275 268 227 205 155 128 90 66 38 25 8 3 0
Choueiri ASCO GU 2022; Bex ESMO 2022; Allaf ESMO 2022; Motzer ESMO 2022
